Abstract
Nonanaplastic thyroid cancers, which include differentiated and medullary thyroid cancers, account for more than 95% of thyroid cancer cases, and the majority are often curable if diagnosed at an early stage. 1 Davies L. Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167 Crossref PubMed Scopus (2634) Google Scholar The use of adjuvant external beam radiation therapy (EBRT) following surgery in patients with nonanaplastic thyroid cancers is uncommon because of its treatment-related morbidity and a paucity of evidence from prospective clinical trials on its efficacy. The indications for its use are still controversial. The current guidelines recommend that EBRT should be considered in patients with gross residual disease postoperatively, those with evidence of aerodigestive invasion, and/or those undergoing multiple and frequent operations because of locally advanced disease. 2 Haugen B.R. Alexander E.K. Bible K.C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26: 1-133 Crossref PubMed Scopus (7355) Google Scholar ,3 Tuttle R.M. Haddad R.I. Ball D.W. et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014; 12: 1671-1680 Crossref PubMed Scopus (119) Google Scholar Trends in Adjuvant External Beam Radiation Therapy for Nonanaplastic Thyroid Cancer in California, 2003-2017Endocrine Practice Vol. 28Issue 7PreviewExternal beam radiation therapy (EBRT) is rarely used to treat patients with differentiated or medullary thyroid cancer. Although EBRT is generally administered to patients with high-risk or unresectable diseases, neither its indications for the use nor the associated outcomes are well-defined. We used a statewide cohort to assess the trends in EBRT use and postradiation outcomes in California. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
